Humacyte, Inc. (HUMA) Gains As Market Dips: What You Should Know
Werte in diesem Artikel
Humacyte, Inc. (HUMA) closed at $2.36 in the latest trading session, marking a +1.29% move from the prior day. The stock outperformed the S&P 500, which registered a daily loss of 0.03%. On the other hand, the Dow registered a loss of 0.11%, and the technology-centric Nasdaq increased by 0.13%. Coming into today, shares of the company had lost 6.43% in the past month. In that same time, the Medical sector gained 1.25%, while the S&P 500 gained 0.6%. The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. It is anticipated that the company will report an EPS of -$0.15, marking a 44.44% rise compared to the same quarter of the previous year. For the full year, the Zacks Consensus Estimates project earnings of -$0.18 per share and a revenue of $8.77 million, demonstrating changes of +82.86% and 0%, respectively, from the preceding year. Investors might also notice recent changes to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. As of now, Humacyte, Inc. holds a Zacks Rank of #2 (Buy). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 88, positioning it in the top 36% of all 250+ industries. The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com. 5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks
Übrigens: US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.
Ausgewählte Hebelprodukte auf Humacyte
Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Humacyte
Der Hebel muss zwischen 2 und 20 liegen
Name | Hebel | KO | Emittent |
---|
Name | Hebel | KO | Emittent |
---|
Quelle: Zacks
Nachrichten zu Humacyte Inc Registered Shs
Analysen zu Humacyte Inc Registered Shs
Keine Analysen gefunden.